Zobrazeno 1 - 5
of 5
pro vyhledávání: '"dolor intercurrente"'
Autor:
María Isabel Vargas, Rafael Salazar, Julia Ferreras, Francisco Rodelas, Jordi Guitart, Vicente De Sanctis, Joan Coma, Pere Estivill, Almudena Sanz, Jordi Moya, Albert Tomás, José Fuentes, Antonio Javier Jiménez, Jordi Folch
Publikováno v:
Drugs in R&D
Objective Our objective was to assess the effect of sublingual fentanyl tablets (SFTs) on pain relief, quality of life, and adverse effects in patients with cancer pain, according to cancer stage and background opioid regimen. Methods Subgroup analys
Autor:
Francisco Rodelas, Jordi Moya, Jordi Guitart, Albert Tomás, María Isabel Vargas, José Fuentes, Joan Coma, Almudena Sanz, Pere Estivill, Rafael Salazar, Vicente De Sanctis, Julia Ferreras, Antonio Javier Jiménez, Jordi Folch
Publikováno v:
Drugs in R&D
Drugs in R&D, Vol 19, Iss 3, Pp 247-254 (2019)
Drugs in R&D, Vol 19, Iss 3, Pp 247-254 (2019)
Introduction Sublingual fentanyl tablets (SFTs) have been shown to be a safe and effective option in controlling breakthrough cancer pain (BTcP). However, further examination is required to investigate the use of SFTs among the elderly. The aim of th
Autor:
Rafael Salazar, Jordi Guitart, María Isabel Vargas, José Fuentes, Vicente De Sanctis, Francisco Rodelas, Julia Ferreras, Joan Coma, Pere Estivill, Albert Tomás, Antonio Javier Jiménez, Jordi Moya, Jordi Folch, Almudena Sanz
Publikováno v:
Drugs in R&D
Introduction Breakthrough pain (BTP) management in patients with cancer is challenging, especially in the elderly. However, no studies examining the influence of age on BTP medication have been conducted. The aim of this work was to investigate the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11a83b72c0c103905ae94c509d5d906a
https://hdl.handle.net/20.500.13003/15640
https://hdl.handle.net/20.500.13003/15640
Autor:
Margarit, Cesar, López, Rafael, Anton, Antonio, Escobar, Yolanda, Casas, Ana, Cruz, Juan Jesús, Galvez, Rafael, Mañas, Ana, Zaragozá, Francisco
Journal Article; Breakthrough cancer pain is defined as transient pain exacerbation in patients with stable and controlled basal pain. Although variable, the prevalence of breakthrough cancer pain is high (33%-95%). According to the American Pain Fou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2636::3df9c73296d5b95145825196e21ea532
https://hdl.handle.net/10668/1420
https://hdl.handle.net/10668/1420
Autor:
J. E. Baños Díez, E. Guardiola Pereira
Publikováno v:
Atención Primaria. (9):617-618